Valuation: Mymetics Corporation

Market Cap 439K 385K 355K 332K 623K 41.39M 635K 4.26M 1.65M 20.46M 1.65M 1.61M 70.93M P/E 2021
-1.86x
P/E 2022 -1.77x
Enterprise Value 72.12M 63.24M 58.29M 54.57M 102M 6.8B 104M 701M 271M 3.36B 271M 265M 11.66B EV / Sales 2021
177x
EV / Sales 2022 78x
Free-Float
99.88%
Yield 2021 *
-
Yield 2022 -
Current year 0
Extreme 0.0003
0
1 year 0
Extreme 0.0003
0
3 years 0
Extreme 0.0003
45.6
5 years 0
Extreme 0.0003
230
10 years 0
Extreme 0.0003
380
Manager TitleAgeSince
Chief Executive Officer 58 18/11/2012
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-.--%-100.00% 45
+0.33%+1.37%+64.03%+119.11% 55.63B
+0.82%+15.05%+79.93%+84.34% 52.25B
+1.36%+0.36%-14.06%-14.69% 23.07B
-1.04%+7.91%+1.61%+419.24% 22.41B
-0.18%+7.20%+32.16%-14.07% 17.32B
-1.10%+4.00%+28.70%-34.51% 15.94B
-3.35%+8.96%+132.20%+290.18% 13.47B
+2.89%+5.51%+27.11%+181.45% 13.77B
+1.31%+0.53%+28.62% - 12.43B
Average +0.10%+4.30%+38.03%+103.45% 22.63B
Weighted average by Cap. +0.26%+5.13%+48.50%+120.17%

Financials

2021 2022
Net sales 430K 377K 348K 325K 610K 40.56M 623K 4.18M 1.62M 20.05M 1.61M 1.58M 69.51M 1.03M 901K 831K 778K 1.46M 96.97M 1.49M 9.99M 3.86M 47.93M 3.86M 3.78M 166M
Net income -4.73M -4.15M -3.82M -3.58M -6.71M -446M -6.85M -45.95M -17.78M -221M -17.76M -17.37M -765M -4.8M -4.21M -3.88M -3.64M -6.82M -453M -6.96M -46.68M -18.06M -224M -18.04M -17.65M -777M
Net Debt 67.1M 58.83M 54.23M 50.77M 95.2M 6.33B 97.18M 652M 252M 3.13B 252M 246M 10.85B 71.68M 62.85M 57.94M 54.24M 102M 6.76B 104M 696M 269M 3.34B 269M 263M 11.59B
Logo Mymetics Corporation
Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.
Employees
2
  1. Stock Market
  2. Stocks
  3. MYMX Stock